WallStreetZenWallStreetZen

NASDAQ: FDMT
4d Molecular Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

FDMT past revenue growth

How has FDMT's revenue growth performed historically?
Company
562.29%
Industry
148.97%
Market
17.57%
FDMT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FDMT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
FDMT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

FDMT earnings and revenue history

Current Revenue
$20.7M
Current Earnings
-$100.8M
Current Profit Margin
-486.6%

FDMT Return on Equity

Current Company
-34.1%
Current Industry
-63.5%
Current Market
188%
FDMT's Return on Equity (-34.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when FDMT announces earnings.

FDMT Return on Assets

Current Company
-31.1%
Current Industry
2.9%
FDMT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

FDMT Return on Capital Employed

Current Company
-31.42%
Current Industry
19.5%
FDMT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

FDMT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
FDMT$20.72M-$95.09M-$100.84M+7.96%N/A
SYRE$886.00k-$337.85M-$338.79M-25.61%N/A
AUTL$1.70M-$152.71M-$208.38M+2.90%N/A
SLNO$0.00-$36.71M-$38.99MN/AN/A
DAWN$0.00-$188.53M-$188.92MN/AN/A
View Top Biotech Stocks

FDMT earnings dates

Next earnings date
May 8, 2024

4d Molecular Therapeutics Earnings & Revenue FAQ

What were FDMT's earnings last quarter?

On Invalid Date, 4d Molecular Therapeutics (NASDAQ: FDMT) reported Q4 2023 earnings per share (EPS) of -$0.77, up 8.33% year over year. Total 4d Molecular Therapeutics earnings for the quarter were -$32.28 million. In the same quarter last year, 4d Molecular Therapeutics's earnings per share (EPS) was -$0.84.

If you're new to stock investing, here's how to buy 4d Molecular Therapeutics stock.

What was FDMT's earnings growth in the past year?

As of Q2 2024, 4d Molecular Therapeutics's earnings has grown year over year. 4d Molecular Therapeutics's earnings in the past year totalled -$100.84 million.

What is FDMT's earnings date?

4d Molecular Therapeutics's earnings date is Invalid Date. Add FDMT to your watchlist to be reminded of FDMT's next earnings announcement.

What was FDMT's revenue last quarter?

On Invalid Date, 4d Molecular Therapeutics (NASDAQ: FDMT) reported Q4 2023 revenue of -$19.00 thousand up 101.52% year over year. In the same quarter last year, 4d Molecular Therapeutics's revenue was $1.25 million.

What was FDMT's revenue growth in the past year?

As of Q2 2024, 4d Molecular Therapeutics's revenue has grown 562.29% year over year. This is 413.32 percentage points higher than the US Biotechnology industry revenue growth rate of 148.97%. 4d Molecular Therapeutics's revenue in the past year totalled $20.72 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.